{"id":690800,"date":"2022-09-30T13:03:15","date_gmt":"2022-09-30T17:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/"},"modified":"2022-09-30T13:03:15","modified_gmt":"2022-09-30T17:03:15","slug":"ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/","title":{"rendered":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n BENSALEM, Pa.<\/span>
\n <\/span>, Sept. 30, 2022<\/span><\/span> \/PRNewswire\/ —\u00a0Law Offices of Howard G. Smith<\/span> announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE<\/a>).<\/p>\n

\n Class Period: <\/b>
\n December 29, 2020<\/span> \u2013 August 3, 2022<\/span>
Lead Plaintiff Deadline:<\/b>October 17, 2022<\/span><\/p>\n

Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith<\/span> to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com<\/a>.<\/p>\n

The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a Biologics License Application for Ampion; (2) inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis at all relevant times.<\/p>\n

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to\u00a0learn more\u00a0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire<\/span>, of Law Offices of Howard G. Smith<\/span>, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania<\/span> 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to\u00a0howardsmith@howardsmithlaw.com<\/a>, or visit our website at www.howardsmithlaw.com<\/a>.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

\n Contacts <\/b>\n <\/div>\n

Law Offices of Howard G. Smith<\/span>
Howard G. Smith, Esquire<\/span>
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com<\/a>
www.howardsmithlaw.com<\/a><\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-301637411.html<\/a><\/p>\n

SOURCE Law Offices of Howard G. Smith<\/span><\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BENSALEM, Pa. , Sept. 30, 2022 \/PRNewswire\/ —\u00a0Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Class Period: December 29, 2020 \u2013 August 3, 2022Lead Plaintiff Deadline:October 17, 2022 Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a Biologics License Application for Ampion; (2) inflated the results of the AP-013 … <\/p>\n

Continue reading “AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690800","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BENSALEM, Pa. , Sept. 30, 2022 \/PRNewswire\/ —\u00a0Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Class Period: December 29, 2020 \u2013 August 3, 2022Lead Plaintiff Deadline:October 17, 2022 Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a Biologics License Application for Ampion; (2) inflated the results of the AP-013 … Continue reading "AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-30T17:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH89088&sd=2022-09-30\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit\",\"datePublished\":\"2022-09-30T17:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH89088&sd=2022-09-30\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/\",\"name\":\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH89088&sd=2022-09-30\",\"datePublished\":\"2022-09-30T17:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH89088&sd=2022-09-30\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH89088&sd=2022-09-30\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/","og_locale":"en_US","og_type":"article","og_title":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire BENSALEM, Pa. , Sept. 30, 2022 \/PRNewswire\/ —\u00a0Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Class Period: December 29, 2020 \u2013 August 3, 2022Lead Plaintiff Deadline:October 17, 2022 Investors suffering losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a Biologics License Application for Ampion; (2) inflated the results of the AP-013 … Continue reading \"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-30T17:03:15+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH89088&sd=2022-09-30","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit","datePublished":"2022-09-30T17:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH89088&sd=2022-09-30","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/","name":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH89088&sd=2022-09-30","datePublished":"2022-09-30T17:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH89088&sd=2022-09-30","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH89088&sd=2022-09-30"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690800"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690800\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}